Syngene International Limited
Syngene International Limited (SYNGENE.NS) Stock Competitors & Peer Comparison
See (SYNGENE.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYNGENE.NS | ₹506.00 | +14.93% | 173.6B | 49.33 | ₹8.76 | +0.29% |
| BIOCON.BO | ₹357.00 | -1.60% | 459.8B | 74.24 | ₹4.88 | +0.14% |
| BIOCON.NS | ₹357.45 | -1.47% | 459.8B | 74.08 | ₹4.89 | +0.14% |
| ANTHEM.NS | ₹764.20 | -1.30% | 435.5B | 90.36 | ₹8.58 | N/A |
| PPLPHARMA.NS | ₹158.18 | -3.82% | 211.9B | -130.20 | -₹1.23 | +0.09% |
| ONESOURCE.NS | ₹1,730.00 | -1.87% | 202.1B | 963.11 | ₹1.83 | N/A |
| SYNGENE.BO | ₹508.20 | +15.50% | 173.7B | 49.35 | ₹8.76 | +0.29% |
| CONCORDBIO.NS | ₹1,142.00 | +6.53% | 118.7B | 38.11 | ₹29.77 | +0.94% |
| CONCORDBIO.BO | ₹1,138.00 | +6.25% | 118.4B | 38.03 | ₹29.76 | +0.94% |
| JUBLINGREA.NS | ₹702.95 | -2.41% | 110.8B | 41.96 | ₹16.75 | +0.71% |
Stock Comparison
SYNGENE.NS vs BIOCON.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, BIOCON.BO has a market cap of 459.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while BIOCON.BO trades at ₹357.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas BIOCON.BO's P/E ratio is 74.24. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.BO's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.BO's competition here
SYNGENE.NS vs BIOCON.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, BIOCON.NS has a market cap of 459.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while BIOCON.NS trades at ₹357.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas BIOCON.NS's P/E ratio is 74.08. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.NS's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.NS's competition here
SYNGENE.NS vs ANTHEM.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, ANTHEM.NS has a market cap of 435.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while ANTHEM.NS trades at ₹764.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas ANTHEM.NS's P/E ratio is 90.36. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ANTHEM.NS's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ANTHEM.NS's competition here
SYNGENE.NS vs PPLPHARMA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, PPLPHARMA.NS has a market cap of 211.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while PPLPHARMA.NS trades at ₹158.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas PPLPHARMA.NS's P/E ratio is -130.20. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PPLPHARMA.NS's ROE of -0.02%. Regarding short-term risk, SYNGENE.NS is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check PPLPHARMA.NS's competition here
SYNGENE.NS vs ONESOURCE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, ONESOURCE.NS has a market cap of 202.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while ONESOURCE.NS trades at ₹1,730.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas ONESOURCE.NS's P/E ratio is 963.11. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ONESOURCE.NS's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ONESOURCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ONESOURCE.NS's competition here
SYNGENE.NS vs SYNGENE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SYNGENE.BO has a market cap of 173.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SYNGENE.BO trades at ₹508.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SYNGENE.BO's P/E ratio is 49.35. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SYNGENE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SYNGENE.BO's competition here
SYNGENE.NS vs CONCORDBIO.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, CONCORDBIO.NS has a market cap of 118.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while CONCORDBIO.NS trades at ₹1,142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas CONCORDBIO.NS's P/E ratio is 38.11. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.NS's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is more volatile compared to CONCORDBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.NS's competition here
SYNGENE.NS vs CONCORDBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, CONCORDBIO.BO has a market cap of 118.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while CONCORDBIO.BO trades at ₹1,138.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas CONCORDBIO.BO's P/E ratio is 38.03. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.BO's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is more volatile compared to CONCORDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.BO's competition here
SYNGENE.NS vs JUBLINGREA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, JUBLINGREA.NS has a market cap of 110.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while JUBLINGREA.NS trades at ₹702.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas JUBLINGREA.NS's P/E ratio is 41.96. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to JUBLINGREA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check JUBLINGREA.NS's competition here
SYNGENE.NS vs BLUEJET.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, BLUEJET.NS has a market cap of 77.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while BLUEJET.NS trades at ₹447.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas BLUEJET.NS's P/E ratio is 26.32. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.NS's ROE of +0.26%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BLUEJET.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.NS's competition here
SYNGENE.NS vs BLUEJET.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, BLUEJET.BO has a market cap of 77.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while BLUEJET.BO trades at ₹445.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas BLUEJET.BO's P/E ratio is 26.34. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.BO's ROE of +0.26%. Regarding short-term risk, SYNGENE.NS is more volatile compared to BLUEJET.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.BO's competition here
SYNGENE.NS vs SUPRIYA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SUPRIYA.BO has a market cap of 56.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SUPRIYA.BO trades at ₹691.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SUPRIYA.BO's P/E ratio is 30.29. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.BO's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SUPRIYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.BO's competition here
SYNGENE.NS vs SUPRIYA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SUPRIYA.NS has a market cap of 56.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SUPRIYA.NS trades at ₹694.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SUPRIYA.NS's P/E ratio is 30.35. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.NS's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SUPRIYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.NS's competition here
SYNGENE.NS vs ZOTA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, ZOTA.NS has a market cap of 39.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while ZOTA.NS trades at ₹1,315.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas ZOTA.NS's P/E ratio is -54.62. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ZOTA.NS's ROE of -0.31%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ZOTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ZOTA.NS's competition here
SYNGENE.NS vs DCAL.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, DCAL.NS has a market cap of 28.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while DCAL.NS trades at ₹179.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas DCAL.NS's P/E ratio is 23.95. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is more volatile compared to DCAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.NS's competition here
SYNGENE.NS vs DCAL.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, DCAL.BO has a market cap of 28.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while DCAL.BO trades at ₹179.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas DCAL.BO's P/E ratio is 23.92. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is more volatile compared to DCAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.BO's competition here
SYNGENE.NS vs PANACEABIO.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, PANACEABIO.NS has a market cap of 22.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while PANACEABIO.NS trades at ₹361.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas PANACEABIO.NS's P/E ratio is -287.40. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to PANACEABIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.NS's competition here
SYNGENE.NS vs PANACEABIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, PANACEABIO.BO has a market cap of 22.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while PANACEABIO.BO trades at ₹362.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas PANACEABIO.BO's P/E ratio is -286.71. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to PANACEABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.BO's competition here
SYNGENE.NS vs TITANBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, TITANBIO.BO has a market cap of 19.6B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while TITANBIO.BO trades at ₹490.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas TITANBIO.BO's P/E ratio is 71.89. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TITANBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TITANBIO.BO's competition here
SYNGENE.NS vs 3BBLACKBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, 3BBLACKBIO.BO has a market cap of 10.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while 3BBLACKBIO.BO trades at ₹1,225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas 3BBLACKBIO.BO's P/E ratio is 19.06. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to 3BBLACKBIO.BO's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to 3BBLACKBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check 3BBLACKBIO.BO's competition here
SYNGENE.NS vs FERMENTA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, FERMENTA.BO has a market cap of 9.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while FERMENTA.BO trades at ₹310.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas FERMENTA.BO's P/E ratio is 10.56. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to FERMENTA.BO's ROE of +0.25%. Regarding short-term risk, SYNGENE.NS is more volatile compared to FERMENTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check FERMENTA.BO's competition here
SYNGENE.NS vs TAKE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, TAKE.NS has a market cap of 6.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while TAKE.NS trades at ₹42.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas TAKE.NS's P/E ratio is -435.60. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.NS's ROE of +0.12%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.NS's competition here
SYNGENE.NS vs TAKE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, TAKE.BO has a market cap of 6.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while TAKE.BO trades at ₹42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas TAKE.BO's P/E ratio is -433.40. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.BO's ROE of +0.12%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.BO's competition here
SYNGENE.NS vs KILPEST.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, SYNGENE.NS is more volatile compared to KILPEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check KILPEST.BO's competition here
SYNGENE.NS vs HALEOSLABS.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, HALEOSLABS.NS has a market cap of 4.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while HALEOSLABS.NS trades at ₹1,475.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas HALEOSLABS.NS's P/E ratio is 22.86. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to HALEOSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.NS's competition here
SYNGENE.NS vs HALEOSLABS.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, HALEOSLABS.BO has a market cap of 4.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while HALEOSLABS.BO trades at ₹1,430.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas HALEOSLABS.BO's P/E ratio is 22.55. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.BO's competition here
SYNGENE.NS vs SMSLIFE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SMSLIFE.BO has a market cap of 4.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SMSLIFE.BO trades at ₹1,430.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SMSLIFE.BO's P/E ratio is 23.94. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.BO's ROE of +0.10%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.BO's competition here
SYNGENE.NS vs SMSLIFE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.NS's competition here
SYNGENE.NS vs LYKALABS.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, LYKALABS.BO has a market cap of 2.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while LYKALABS.BO trades at ₹59.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas LYKALABS.BO's P/E ratio is 104.05. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to LYKALABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.BO's competition here
SYNGENE.NS vs LYKALABS.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, LYKALABS.NS has a market cap of 2.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while LYKALABS.NS trades at ₹59.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas LYKALABS.NS's P/E ratio is -355.18. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to LYKALABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.NS's competition here
SYNGENE.NS vs ALFAVIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, ALFAVIO.BO has a market cap of 471.3M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while ALFAVIO.BO trades at ₹14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas ALFAVIO.BO's P/E ratio is -498.33. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ALFAVIO.BO's ROE of -0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ALFAVIO.BO's competition here
SYNGENE.NS vs SAMSRITA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SAMSRITA.BO has a market cap of 242.6M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SAMSRITA.BO trades at ₹16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SAMSRITA.BO's P/E ratio is -4.11. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SAMSRITA.BO's ROE of -0.61%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SAMSRITA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SAMSRITA.BO's competition here
SYNGENE.NS vs TRABI.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, TRABI.BO has a market cap of 215.2M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while TRABI.BO trades at ₹2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas TRABI.BO's P/E ratio is -11.36. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TRABI.BO's ROE of -0.19%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TRABI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TRABI.BO's competition here
SYNGENE.NS vs STARSOURCE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, STARSOURCE.BO has a market cap of 185.7M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while STARSOURCE.BO trades at ₹123.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas STARSOURCE.BO's P/E ratio is -1.53. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, SYNGENE.NS is more volatile compared to STARSOURCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check STARSOURCE.BO's competition here
SYNGENE.NS vs VANTABIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, VANTABIO.BO has a market cap of 115.6M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while VANTABIO.BO trades at ₹16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas VANTABIO.BO's P/E ratio is -2.38. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to VANTABIO.BO's ROE of -0.34%. Regarding short-term risk, SYNGENE.NS is more volatile compared to VANTABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check VANTABIO.BO's competition here
SYNGENE.NS vs GVBL.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, GVBL.BO has a market cap of 74.1M. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while GVBL.BO trades at ₹24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas GVBL.BO's P/E ratio is -220.45. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to GVBL.BO's ROE of +0.03%. Regarding short-term risk, SYNGENE.NS is more volatile compared to GVBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check GVBL.BO's competition here
SYNGENE.NS vs SERVOTEACH.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 173.6B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, SYNGENE.NS is priced at ₹506.00, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 49.33, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SERVOTEACH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SERVOTEACH.BO's competition here